Background

Evaluating the impact of chromium picolinate supplementation on glycemic status, lipid profile, inflammatory markers and fetuin-A in patients with non-alcoholic fatty liver disease (NAFLD).

Methods

In present research, participants (N = 46) were randomized to (400 mcg/day, n = 23) chromium picolinate and placebo (n = 23) for 3 months.

Results

Glucose indices, and lipid profiles, inflammatory biomarker and fetuin-A were measured before and after the intervention. Chromium reduced triglyceride (TG), atherogenic index of plasma (AIP), very-low-density lipoprotein (VLDL), insulin, homeostatic model assessment for insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), interleukin (IL) -6, tumor necrosis factor-alpha (TNF-α) and fetuin-A significantly compared to placebo group (p < 0.05). Furthermore, chromium significantly increased the quantitative insulin sensitivity check index (QUICKI). There were no significant differences in total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), fasting blood sugar (FBS), Hemoglobin A1c (HbA1C), interleukin (IL)-17 between the two groups (p < 0.05).

Conclusion

Chromium picolinate significantly decreased TG, insulin, HOMA-IR, fetuin-A, the number of inflammatory factors, and increased QUICKI without changing FBS, HbA1C, TC, LDL, HDL, IL-17 levels and liver steatosis intensity in patients with NAFLD. Further studies by examining the effect of different doses of chromium and mechanisms of cellular action, would help further clarify the subject.

中文翻译：

---

补充吡啶甲酸铬对非酒精性脂肪肝患者血清胎球蛋白 A、代谢和炎症因子影响的初步研究：一项双盲、安慰剂对照试验

背景

评估补充吡啶甲酸铬对非酒精性脂肪性肝病 (NAFLD) 患者血糖状态、血脂状况、炎症标志物和胎球蛋白 A 的影响。

方法

在目前的研究中，参与者（N = 46）被随机分配到（400 mcg/天，n = 23）吡啶甲酸铬和安慰剂（n = 23）3 个月。

结果

在干预前后测量葡萄糖指数、脂质谱、炎症生物标志物和胎球蛋白-A。铬降低甘油三酯 (TG)、血浆致动脉粥样硬化指数 (AIP)、极低密度脂蛋白 (VLDL)、胰岛素、胰岛素抵抗的稳态模型评估 (HOMA-IR)、高敏 C 反应蛋白 (hs-CRP) )、白细胞介素 (IL) -6、肿瘤坏死因子-α (TNF-α) 和胎球蛋白-A 与安慰剂组相比显着 (p < 0.05)。此外，铬显着增加了定量胰岛素敏感性检查指数 (QUICKI)。总胆固醇（TC）、高密度脂蛋白胆固醇（HDL）、低密度脂蛋白胆固醇（LDL）、空腹血糖（FBS）、血红蛋白 A1c（HbA1C）、白细胞介素（IL）-17 之间无显着差异。两组（p < 0.05）。

结论

吡啶甲酸铬显着降低了 NAFLD 患者的 TG、胰岛素、HOMA-IR、胎球蛋白-A、炎症因子的数量，并增加了 QUICKI，而不改变 FBS、HbA1C、TC、LDL、HDL、IL-17 水平和肝脏脂肪变性强度。通过检查不同剂量铬的影响和细胞作用机制的进一步研究，将有助于进一步阐明这一主题。